BPG is committed to discovery and dissemination of knowledge
Featured Articles
5/8/2017 9:16:43 AM | Browse: 1061 | Download: 1945
Publication Name World Journal of Nephrology
Manuscript ID 27100
Country Canada
ISSN 2220-6124 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Urology & Nephrology
Manuscript Type Case Control Study
Article Title Any link of gout disease control among hypertensive patients and onset of end-stage renal disease? Results from a population-based study
Manuscript Source Unsolicited Manuscript
All Author List Sylvie Perreault, Javier Nuevo, Scott Baumgartner and Robert Morlock
Funding Agency and Grant Number
Corresponding Author Sylvie Perreault, BPharm, PhD, Full Professor, Faculty of Pharmacy, University of Montreal, Case Postale 6128, Succursale Centre-Ville, Montreal, QC H3C 3J7, Canada. sylvie.perreault@umontreal.ca
Key Words Allopurinol; End-stage renal disease; Gout; Hyperuricemia; Medication adherence; Serum uric acid
Core Tip The question of whether serum uric acid has a pathogenic role in the onset and progression of chronic kidney disease (CKD) remains unanswered. Hyperuricemia and gout is common in CKD, and treatment adherence in gout patients is suboptimal and therefore a therapeutic challenge. Our population-based study assessed the impact of gout disease control on the risk of end stage renal disease (ESRD). Our study suggest that adherence to allopurinol of ≥ 80% as a proxy for gout control is associated with a significant, 65% reduction in the risk of ESRD onset.
Publish Date 2017-05-04 18:19
Citation Perreault S, Nuevo J, Baumgartner S, Morlock R. Any link of gout disease control among hypertensive patients and onset of end-stage renal disease? Results from a population-based study. World J Nephrol 2017; 6(3): 132-142
URL http://www.wjgnet.com/2220-6124/full/v6/i3/132.htm
DOI http://dx.doi.org/10.5527/wjn.v6.i3.132
Full Article (PDF) WJN-6-132.pdf
Full Article (Word) WJN-6-132.doc